Skip to main content

Pfizer — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

100
Companies
$4.7B
Total invested
$93.8M
Avg. check
19
Industries
Biotechnology 22Pharmaceutical 10Health Care 10Therapeutics 9Biopharma 7Life Science 5+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 25–48 of 100
Vedanta Biosciences
April 2024

Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.

Biotechnology · Cambridge$3.9M Grant
Curve Therapeutics
February 2024

Curve develops an innovative screening platform.

Biotechnology · Southampton$51.4M Series A
NexImmune
February 2024

NexImmune is a biopharmaceutical company developing novel immuno-therapeutics based on the proprietary artificial immune technology.

Biopharma · Gaithersburg$3.7M Post-IPO Equity
Vivet Therapeutics
February 2024

Vivet Therapeutics is a biotechnology company developing gene therapy treatments for orphan diseases.

Biopharma · Paris$5.3M Grant
Superfluid Dx
December 2023

Superfluid Dx is a biotechnology company developing novel blood-based early detection.

Biotechnology · San DiegoSeries A
VitaDAO
November 2023

A decentralized collective funding early stage aging research & spinning out longevity biotech startups to extend healthy lifespan

Biotechnology · Ottawa$2.0M Seed
Cerevel Therapeutics
October 2023

Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.

Biotechnology · Boston$450.0M Post-IPO Equity
Caribou Biosciences
July 2023

Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.

Biotechnology · Berkeley$125.0M Post-IPO Equity
Zentalis Pharmaceuticals
June 2023

Zentalis is a pharmaceutical company focused on developing clinical therapeutics for cancer patients.

Biopharma · New York$235.5M Post-IPO Equity
Mozart Therapeutics
June 2023

Mozart is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases.

Biotechnology · Seattle$25.0M Series A
Flare Therapeutics
March 2023

Flare Therapeutics is a biotech startup that creates precision therapies for cancer and other disorders by targeting transcription factors.

Biopharma · Cambridge$123.0M Series B
GeneDx
January 2023

GeneDx uses artificial intelligence and machine learning to analyze patient data to provide insights to transform the practice of medicine.

Analytics · Stamford$150.0M Post-IPO Equity
Carrick Therapeutics
December 2022

Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated.

Biotechnology · Boston$60.0M Series C
Nucleome Therapeutics
October 2022

Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases

Biotechnology · Oxford$42.0M Series A
DEM BioPharma
June 2022

DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.

Biotechnology · Cambridge$70.0M Series A
Arkuda Therapeutics
February 2022

Arkuda Therapeutics is a pharmaceutical company.

Biotechnology · Cambridge$64.0M Series B
Anaveon
December 2021

Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.

Therapeutics · Bottmingen$119.7M Series B
Kestrel Therapeutics
December 2021

Kestrel Therapeutics is a medical research and devenlopment company that offers treatment solutions for RAS cancers.

Biopharma · Allston$40.0M Series A
Parthenon Therapeutics
November 2021

Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.

Biotechnology · Cambridge$65.0M Series A
Levicept
September 2021

Levicept develops biological agent for the treatment of chronic pain.

Biopharma · Sandwich$47.8M Series B
Anjarium Biosciences
September 2021

Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.

Biotechnology · Schlieren$60.4M Series A
Strata Oncology
July 2021

Strata Oncology is a precision oncology company dedicated to transforming cancer care.

Biotechnology · Ann Arbor$90.0M Series C
Imara
July 2021

Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.

Biopharma · Cambridge$50.0M Post-IPO Equity
MindImmune Therapeutics
March 2026

MindImmune Therapeutics is a pharmaceutical company developing drugs to treat diseases of the central nervous system.

Biotechnology · Providence$5.0M Grant

Where Pfizer invests

Biotechnology22
Pharmaceutical10
Health Care10
Therapeutics9
Biopharma7
Life Science5

About Pfizer's portfolio

How many companies has Pfizer invested in?▸

Pfizer has invested in 100 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Pfizer invest in?▸

Pfizer's top investment sectors include Biotechnology, Pharmaceutical, Health Care, Therapeutics, Biopharma. The firm invests across 19 different industry categories.

What is Pfizer's largest investment?▸

Among tracked funding rounds, Cerevel Therapeutics received $450.0M in a Post-IPO Equity round. Pfizer's total known invested capital is $4.7B.

What is the average investment size for Pfizer?▸

Pfizer's average investment size is $93.8M across its portfolio of 100 companies.

What are Pfizer's most recent investments?▸

Recent Pfizer portfolio additions include Vedanta Biosciences, Curve Therapeutics, NexImmune, Vivet Therapeutics, Superfluid Dx. These companies were founded in 2020 or later.

Reach the founders behind these 100 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →